About Sevion Therapeutics (OTCMKTS:SVON)
Eloxx Pharmaceuticals, Inc., formerly Sevion Therapeutics, Inc., is a development-stage biotech company. The Company is engaged in building and developing a portfolio of therapeutics, from both internal discovery and acquisition, for the treatment of cancer and immunological diseases. The Company is engaged in the development and licensing of technology to discover and engineer monoclonal antibodies. The Company's product candidates are derived from multiple technology platforms, such as cell-based arrayed antibody discovery, ultralong antibody scaffolds and Chimerasome nanocages. The Company has various antibodies in its preclinical pipeline. The Company's antibody therapeutic candidates target the potassium channel, voltage dependent (Kv1.3) ion channel, which is essential in the pathogenesis of several autoimmune and inflammatory disorders. Other antibodies in its pipeline target cell surface molecules involved in cancer progression.
Industry, Sector and Symbol
Trailing P/E Ratio-0.0610997963340122
Forward P/E RatioN/A
Sales & Book Value
Price / Sales209.85
Price / CashN/A
Book Value$0.03 per share
Price / Book10.00
Return on Equity-264.80%
Return on Assets-81.73%
Sevion Therapeutics (OTCMKTS:SVON) Frequently Asked Questions
What is Sevion Therapeutics' stock symbol?
Sevion Therapeutics trades on the OTCMKTS under the ticker symbol "SVON."
How were Sevion Therapeutics' earnings last quarter?
Who are some of Sevion Therapeutics' key competitors?
Some companies that are related to Sevion Therapeutics include Deciphera Pharmaceuticals (DCPH), American Renal Associates (ARA), AtriCure (ATRC), Adamas Pharmaceuticals (ADMS), Abeona Therapeutics (ABEO), ANI Pharmaceuticals (ANIP), Cryolife (CRY), Tabula Rasa HealthCare (TRHC), LeMaitre Vascular (LMAT), Rocket Pharmaceuticals (RCKT), Voyager Therapeutics (VYGR), Inflarx (IFRX), ChemoCentryx (CCXI), Menlo Therapeutics (MNLO), Invacare (IVC), Uniqure (QURE), AC Immune (ACIU) and AMAG Pharmaceuticals (AMAG).
Who are Sevion Therapeutics' key executives?
Sevion Therapeutics' management team includes the folowing people:
- Robert E. Ward, Chairman of the Board, Chief Executive Officer (Age 60)
- Gregory L. Weaver, Chief Financial Officer, Principal Accounting Officer (Age 61)
- Pedro Huertas, Chief Medical Officer
- Zafrira Avnur, Director
- Tomer Kariv, Director
- Martijn Kleijwegt, Director
- Ran Nussbaum, Director (Age 44)
- Steven Rubin, Director (Age 57)
Has Sevion Therapeutics been receiving favorable news coverage?
Media stories about SVON stock have trended somewhat negative this week, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Sevion Therapeutics earned a news impact score of -0.03 on Accern's scale. They also gave media stories about the company an impact score of 45.88 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
How do I buy shares of Sevion Therapeutics?
Shares of SVON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sevion Therapeutics' stock price today?
One share of SVON stock can currently be purchased for approximately $0.30.
How big of a company is Sevion Therapeutics?
Sevion Therapeutics has a market capitalization of $367.62 million and generates $80,000.00 in revenue each year. The company earns $-5,790,000.00 in net income (profit) each year or ($4.91) on an earnings per share basis. Sevion Therapeutics employs 4 workers across the globe.
How can I contact Sevion Therapeutics?
Sevion Therapeutics' mailing address is 950 Winter St, WALTHAM, MA 02451-1424, United States. The company can be reached via phone at +1-858-9090749 or via email at [email protected]
MarketBeat Community Rating for Sevion Therapeutics (SVON)MarketBeat's community ratings are surveys of what our community members think about Sevion Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Sevion Therapeutics (OTCMKTS:SVON) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Sevion Therapeutics (OTCMKTS:SVON) Earnings History and Estimates Chart
Sevion Therapeutics (OTCMKTS SVON) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Sevion Therapeutics (OTCMKTS:SVON) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Sevion Therapeutics (OTCMKTS:SVON)
No dividend announcements for this company have been tracked by MarketBeat.com
Sevion Therapeutics (OTCMKTS SVON) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 7.70%
Sevion Therapeutics (OTCMKTS SVON) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|9/29/2015||Phillip Md Et Al Frost||Director||Buy||35,000||$0.61||$21,350.00|| |
Sevion Therapeutics (OTCMKTS SVON) News Headlines
Sevion Therapeutics (OTCMKTS:SVON) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Sevion Therapeutics (OTCMKTS:SVON) Income Statement, Balance Sheet and Cash Flow Statement
Sevion Therapeutics (OTCMKTS SVON) Stock Chart for Monday, March, 19, 2018